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Chronic Lymphocytic Leukemia
Introduction
Chronic lymphocytic leukemia (CLL) is the most common
leukemia in the Western world and is characterized by the
presence of long-lived mature B cells with the distinct pheno-
type CD19+CD5+CD23+IgMloFMC7-.1 Although deregulation
of anti-apoptotic Bcl-2 family members indicates that CLL
develops due to inappropriate accumulation of monoclonal B
cells,1,2 assessment of cell turnover reveals that CLL cells also
undergo enhanced cell division within proliferation centers of
lymphoid organs. This occurs through CLL cell interaction
with the stromal niche, antigen and co-stimulation by activat-
ed CD4+ T lymphocytes expressing CD40 ligand (CD40L),
and interleukin (IL)-4.3-5 CLL is, therefore, a dynamic disease
with significant rates of proliferation and death and complex
in vitro and in vivo disease model systems are required to gain
a fundamental understanding of the disease and design suit-
able therapies.  
Clinically, CLL is a heterogeneous disease that can follow
an indolent or aggressive course. Over the past decade it has
been established that two major prognostic subtypes of CLL
can be defined by the mutational status of the variable
region of the immunoglobulin heavy chain gene (IGVH).
Favorable outcomes are associated with the expression of
mutated IGVH genes, while cases harboring unmutated
IGVH genes, which can also express the tyrosine kinase,
zeta-associated protein 70 (ZAP-70) and CD38, display more
aggressive disease and more frequently require therapeutic
intervention.6,7 ZAP-70 expression correlates strongly with
unmutated IGVH.8
While a wealth of research into the biology of CLL has
shown the importance of a number of proteins, particularly
those assisting in chemoresistance (eg., Mcl-1, absence of
p53), no single genetic event has been linked to the initiation
of CLL. Due to the heterogeneity within CLL, it is likely that
a number of in vitro and in vivo models will be required to elu-
cidate different aspects of the disease and gain a fuller under-
standing of the initiation, maintenance and progression of
CLL. We previously demonstrated that retroviral-transduc-
tion of hematopoietic progenitor cells (HPC) with a kinase
dead PKCa construct (PKCa-KR) and subsequent culture
either in an in vitro B-cell generation culture (OP9 co-culture)
or in vivo resulted in the generation of CLL-like cells and dis-
ease,9 indicating that modulation of PKCa function may play
a role in CLL cell development. In the present study, we fur-
ther characterize the disease generated upon expression of
PKCa-KR in HPC and demonstrate that the CLL-like disease
phenotypically resembles poor prognosis CLL.1
Dissemination of CLL-like cells occurred in lymphoid organs
with abnormal distribution in the spleens, and increased CLL-
like cells in lymphoid organs, compared with control HPC. In
addition, the CLL-like cells had undergone limited/no somat-
ic hypermutation in IGVH genes and exhibited up-regulation
of ZAP-70 expression and PKCbII expression accompanying
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Overwhelming evidence identifies the microenvironment as a critical factor in the development and progression
of chronic lymphocytic leukemia, underlining the importance of developing suitable translational models to study
the pathogenesis of the disease. We previously established that stable expression of kinase dead protein kinase C
alpha in hematopoietic progenitor cells resulted in the development of a chronic lymphocytic leukemia-like dis-
ease in mice.  Here we demonstrate that this chronic lymphocytic leukemia model resembles the more aggressive
subset of chronic lymphocytic leukemia, expressing predominantly unmutated immunoglobulin heavy chain
genes, with upregulated tyrosine kinase ZAP-70 expression and elevated ERK-MAPK-mTor signaling, resulting in
enhanced proliferation and increased tumor load in lymphoid organs. Reduced function of PKCa leads to an up-
regulation of PKCbII expression, which is also associated with a poor prognostic subset of human chronic lym-
phocytic leukemia samples. Treatment of chronic lymphocytic leukemia-like cells with the selective PKCb
inhibitor enzastaurin caused cell cycle arrest and apoptosis both in vitro and in vivo, and a reduction in the leukemic
burden in vivo. These results demonstrate the importance of PKCbII in chronic lymphocytic leukemia-like disease
progression and suggest a role for PKCa subversion in creating permissive conditions for leukemogenesis.  
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ABSTRACT
disease maturation, which may account for the prolifera-
tion/survival advantage of these cells.9 Selective targeting
of PKCb activity with enzastaurin resulted in the induc-
tion of cell cycle arrest and apoptosis in vitro and in vivo. 
Methods
Animals and cells  
Wild-type ICR and C57BL/6 mice were purchased from Harlan
Laboratories Ltd. (Oxon, UK), and recombinase activating gene-1-
deficient (RAG-1-/-) mice were bred and maintained in-house at the
University of Glasgow Central Research Facilities (Glasgow, UK).
Splenic cell suspensions were generated from aged TCL-1 mice
with manifest leukemia (12-month old Em-TCL-1 mice) maintained
in the Queen Mary University of London animal facility.10 Timed-
pregnant ICR or C57BL/6 mice were generated and fetal liver
extracted at E14. Animals were maintained under standard animal
housing conditions in accordance with local and Home Office reg-
ulations. Peripheral blood samples were obtained, after informed
consent, from patients with a clinically confirmed diagnosis of CLL
(Online Supplementary Table S1). The studies were approved by the
West of Scotland Research Ethics Service, NHS Greater Glasgow
and Clyde, UK. CLL lymphocytes were isolated as previously
described.11 Normal peripheral blood samples were obtained, after
informed consent, from buffy coats of healthy donors and B lym-
phocytes were separated with MACS human CD19 MicroBeads
(Miltenyi Biotec Ltd., Surrey, UK). Leukemic B cells were purified
from mouse spleens with MACS mouse CD19 MicroBeads
(Miltenyi Biotec Ltd.). GP+E.86 packaging cells produce retrovirus
encoding green fluorescent protein (GFP) alone (MIEV-empty vec-
tor control) or dominant negative PKCa (PKCa-KR).12
In vitro or in vivo B-cell generation  
HPC isolated from E14 fetal liver were prepared and retroviral-
ly-transduced as described previously.13 Retrovirally-transduced
HPC were cultured on a layer of OP9 cells for B-cell development
in the presence of IL-7 (Peprotech EC Ltd., London, UK), or adop-
tively transferred as described previously.13 Mice were sacrificed
between 5 to 8 weeks after injection and the bone marrow, spleen,
lymph nodes and blood were collected for analyses. 
Flow cytometric analysis  
Antibodies were purchased from BD Biosciences (Oxford, UK)
unless otherwise stated. Biotin-conjugated antibodies were detect-
ed by streptavidin-Pacific blue (Invitrogen, Paisley, UK). Single cell
suspensions were prepared and stained as described previously.13
The cells were acquired on a FACSCantoII (BD Biosciences) using
the FACSDiva software package (BD Biosciences) and FlowJo soft-
ware package (Tree Star Inc, Ashland, OR, USA) to analyze the
data.  All data shown were lymphocyte-gated by size and
hematopoietic lineage gated by CD45+ cells. Detailed methods are
available in the Online Supplement.
Histology and immunohistochemistry
Spleens were collected from HPC-reconstituted mice and con-
trol RAG-1-/- mice after 5 weeks and fixed in neutral buffered for-
malin (Sigma-Aldrich) at 4°C overnight and embedded in paraffin
following a standard ethanol and xylene protocol. Tissue sections
were scanned with the SlidePath Digital Pathology Solutions sys-
tem (Leica Microsystems Ltd., Milton Keynes, UK). Detailed
methods are available in the Online Supplement.
Cell cycle, apoptosis and proliferation analysis
Cell cycle was analyzed by detecting DNA content, visualized
with propidium iodide (PI) intercalation as described previously.9 A
BrdU incorporation assay was performed using the Cell
Proliferation Elisa BrdU kit (Roche Diagnostics, West Sussex, UK),
following the manufacturer’s protocol. Apoptosis was determined
by analyzing annexin V/DAPI staining (BD Biosciences), as previ-
ously described.14
Determination of the mutational status of IGVH
C57BL/6 fetal liver-derived HPC were prepared, retrovirally-
transduced and transferred into RAG-1-/- mice with C57BL/6-
derived thymocytes. Mice were sacrificed at 5 weeks after injec-
tion. GFP+ splenic cells were isolated by cell sorting on a FACSAriaI
(BD Biosciences), RNA was extracted using an RNAeasy kit
(Qiagen, Manchester, UK) and reverse transcribed with AMV
(Roche Diagnostics) using oligo(dT)15 primers. cDNA was ampli-
fied with PCR primer combinations and cycles described else-
where.15 Successfully amplified PCR products were cloned into
pCRII-Blunt-TOPO (Invitrogen) and sequenced with M13
reverse/forward primers. The data acquired were analyzed using
IMGT (www.imgt.org).
Western blots
MIEV- or PKCa-KR-HPC co-cultures were removed from the
OP9 layer and placed on plastic in complete medium for 2 h in order
to separate cells from adherent OP9 cells. Lysates containing equal
amounts of protein were separated by sodium dodecylsulfate-poly-
acrylamide gel electrophoresis, transferred onto polyvinyl difluo-
ride membrane, and blocked as described previously.16 All antibod-
ies were obtained from Cell Signaling Technologies (Danvers, MA,
USA) except anti-PKCbI (E-3) and anti-PKCbII (sc-210) antibodies,
which were obtained from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). The blots were developed with an Immun-StarTM
Western CTM HRP chemiluminescence kit, and imaged with the
Molecular Imager® ChemiDocTM XRS system (Bio-Rad
Laboratories, Hempstead, UK).
Quantitative real-time polymerase chain reaction  
Quantitative real-time polymerase chain reaction (PCR) was per-
formed in triplicate with the 7900HT Fast Real-Time PCR system
(Applied Biosystems, Warrington, UK) using the Taqman Gene
Expression Assay probe and primer set, and analyzed on the ABI
Prism 7900HT (Applied Biosystems) for mouse prkcb and aicda,
with gapdhwas used as a reference gene, as described previously.16
In vitro and in vivo drug treatment
In vitroMIEV- or PKCa-KR-HPC co-cultures were removed from
the OP9 layer and density-centrifuged with Lympholyte-Mammal
to remove dead cells. One million cells were cultured in the pres-
ence of IL-7 (10 ng/mL) and treated with enzastaurin (LY317615, a
kind gift from Eli Lilly) at the indicated concentrations.  Dimethyl
sulfoxide (DMSO) was added as a vehicle, no-drug control. For in
vivo studies, CLL-like disease was generated in mice as described
above. Mice with confirmed leukemia (≥ 0.4% GFP+CD19+ in the
blood) were treated 4 – 6 weeks after injection with 75 mg/kg enza-
staurin or vehicle (5% dextrose in water), twice a day for up to 21
days by oral gavage and then sacrificed for analyses.
Results
Infiltration of chronic lymphocytic leukemia-like cells in
the lymphoid organs of mice adoptively transferred with
PKCa-KR-expressing hematopoietic progenitor cells 
We have previously shown that PKCa-KR expression in
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wild-type mouse HPC, and subsequent culture in an in
vitro B-cell generating environment (HPC-OP9 co-culture)
leads to the generation of a population of cells phenotypi-
cally similar to human CLL (CD19+CD23+CD5+sIgMlo;
Figure 1A9). During the in vitro development of B cells, up-
regulation of the mature B lineage marker CD23 was evi-
dent on both MIEV- and PKCa-KR-expressing cells by day
(d) 10 of co-culture, with significantly higher expression
noted on PKCa-KR-expressing cells (Figure 1B). CD23
expression was not accompanied by IgM up-regulation,
but was instead associated with higher expression of CD5
in PKCa-KR-expressing cells (Figure 1C). Moreover, the
percentage of the CD19+CD5+ population increased signif-
icantly during the PKCa-KR cultures, while remaining
unchanged in the MIEV cultures (Online Supplementary
Figure S1).
Reconstitution of mice with an increasing number of
PKCa-KR-HPC (1x105, 3x105, 5x105) significantly reduced
mouse survival, with the majority of mice succumbing to
a CLL-like disease between 6 – 9 weeks when reconstitut-
ed with 3x105 PKCa-KR-HPC. As expected, reconstitution
of mice with 5x105 MIEV-HPC did not affect survival
(Figure 2A). Analysis of spleen size suggested an increase
in cell number in PKCa-KR-HPC-reconstituted mice, due
to an increase in spleen weight compared with that in
MIEV-HPC and RAG-/- mice (Figure 2B).  Analysis of the
splenic architecture from MIEV- or PKCa-KR-HPC-recon-
stituted mice revealed the development of lymphoid fol-
Reduced PKCα induces progressive CLL-like disease
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Figure 1. PKCa-KR-expressing cells phenotypically resemble human CLL cells according to surface protein expression. (A) MIEV- or PKCa-KR-
HPC-OP9 co-cultures were analyzed by flow cytometry at d10. FACS plots shown are live- and size- (FSC/SSC) and hemopoietic lineage
(CD45+)-gated prior to analysis for CD5 vs. CD19, CD23 vs. CD19 and IgM vs. CD19 as indicated. Percentages are indicated in the corner of
the quadrants. (B) The mean fluorescence intensity (MFI) of CD19, CD5, CD23 and IgM was calculated for a minimum of three individual bio-
logical replicates. Data are presented as mean (± SEM). P values were generated using a Student unpaired t-test to compare groups (*P<0.05;
**P<0.005; ***P<0.001). (C) A histogram comparing the surface expression of CD23 on GFP+CD45+CD19+CD5+-gated MIEV or PKCa-KR
cells, against relative cell number (RCN).
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licular structures that were absent from the RAG-/- host
spleen (Figure 2C). However PKCa-KR follicular cells
were unusually distributed resulting in a disorganized
splenic architecture, as indicated by H&E staining of
splenic sections and immunohistochemistry staining for
the B lineage marker B220, which co-stains with CD19+
cells in both MIEV- and PKCa-KR-transduced cells (Figure
2C, Online Supplementary Figure S2). H&E staining also
revealed lymphocyte infiltration in the liver of PKCa-KR
mice, but not MIEV mice (Online Supplementary Figure S3).
Flow cytometric analyses of retrovirally-transduced GFP+
cells that populate the lymphoid organs of reconstituted
mice revealed a small population of GFP+CD19+CD5- B lin-
eage cells in the bone marrow, spleen and blood of MIEV-
HPC mice. However, in PKCa-KR-HPC mouse organs and
blood, the majority of CD19+ B cells were CD5+, similar to
CLL cells (Figure 2D,E). The percentage of
GFP+CD19+CD5+ B cells detected in blood, spleen, bone
marrow and lymph nodes was significantly higher in
PKCa-KR-mice than in GFP+CD19+ MIEV control mice
(Figure 2E). Moreover, the GFP+CD19+CD5+ B-cell popula-
tion was detectable in blood at 3 weeks and increased over
time (Online Supplementary Figure S4).
PKCa-KR transduced cells exhibit features of the poor
prognostic subgroup of chronic lymphocytic leukemia
patients 
Examination of ZAP-70 expression levels in in vitro-gen-
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Figure 2. CLL-like cells dis-
seminate into primary and
secondary lymphoid organs.
MIEV- and PKCa-KR-HPCs
were injected (i.p.) into RAG-
1-/- neonates. (A) Kaplan-
Meier curves comparing the
survival rates in mice adop-
tively-transferred with MIEV-
HPCs [500K-pale gray line,
square (n=5) or PKCa-KR-
HPC (500K-mid-gray line, tri-
angle (n=5); 300K-dark gray
line, circle (n=6); 100K-dot-
ted line (n=4)]. Log-rank
(Mantel-Cox) test showed an
overall significant difference
(P=0.0013). The log-rank test
of trend revealed a signifi-
cant linear trend between the
number of cells injected and
the survival of mice
(P=0.0001). (B) Spleen
weights from RAG-/-, MIEV-
HPC and PKCα-KR-HPC mice
are shown as a percentage of
total body weight. A Student
unpaired t-test was per-
formed; *P<0.05.  The
graphs were generated from
six spleens per condition. (C)
Five-week post-reconstitution
mice were sacrificed.
Paraffin-embedded spleens
from RAG-/- host mice (top)
MIEV (middle) or PKCa-KR
(bottom) were sectioned and
stained with either H&E (left)
or anti-B220 antibody
(brown; right); 40 x magnifi-
cation shown. (D) Single cell
suspensions were prepared
from organs as indicated and
analyzed by flow cytometry
for CLL cell markers, CD19
and CD5 after live- and size-
(FSC/SSC) and GFP+CD45+
gating. (E) The percentage of
GFP+CD19+ cells or
GFP+CD19+CD5+ cells within
total hematopoietic CD45+
cells in the indicated organs
is shown for mice reconstitut-
ed with MIEV- or PKCa-KR-
HPC as indicated. A Student
unpaired t-test was per-
formed; *P<0.05, **
P<0.005, ***P<0.001. The
graphs were generated using
data from ten individual
mice.  
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erated CD19+ B cells and splenic B cells isolated from
PKCa-KR-HPC mice by flow cytometry revealed that
PKCa-KR-expressing cells up-regulated ZAP-70 expres-
sion compared to control B cells and the established CLL
mouse model Em-TCL-1 (Figure 3A,B). Low level ZAP-70
expression is observed in MIEV-expressing cells, which
has previously been described in normal mature B cells
(Figure 3A17). Analysis of IGVHmutational status revealed
that the majority of PKCa-KR-expressing cells isolated
from spleens had unmutated IGVH genes (6/8 sequences),
compared with half (4/8 sequences) of the MIEV-express-
ing cells (Table 1). Interestingly, the IGVH genes contained
longer CDR3 regions in PKCa-KR-expressing cells.
Western blotting analysis revealed an activation of the
ERK-MAPK and mTorc-1 pathways, as indicated by ele-
vated phosphorylation of ERK1/2 and S6 in PKCa-KR cells
(Figure 3C). Prolonged activation of the MEK/ERK path-
way is associated with anti-apoptotic characteristics of
CLL cells.18 PKCa-KR cells also exhibited an elevated pro-
liferative capacity compared with control B cells, both in
vitro and in vivo (Figure 3D,E). Supporting this, aicda expres-
sion, which has been associated with increased CLL cell
proliferation,19,20 was significantly increased in GFP+CD19+
cells expressing PKCa-KR at the later stages of culture
compared to MIEV-expressing cells (Figure 3F). 
We previously demonstrated that PKCa-KR-transduced
cells exhibited reduced PKC activity during the early
stages of the OP9 co-culture, as expected (Figure 4A, left).9
However we observed an elevation in PKC activity later in
the co-cultures, at d17 (Figure 4A, right and 4B). As PKCbII
up-regulation has previously been associated with poor
prognosis in CLL patients, we analyzed PKCb expres-
Reduced PKCα induces progressive CLL-like disease
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Figure 3. PKCa-KR-transduced CLL-like cells resemble poor prognostic CLL patients’ samples. (A) MIEV- or PKCa-KR-HPC were analyzed by
flow cytometry for intracellular levels of ZAP-70 at d12 of co-culture.  Solid line, PKCa-KR; dotted line, MIEV; shaded, isotype control.  A rep-
resentative blot of three independent cultures is shown.  (B) The percentage of ZAP-70+ cells was analyzed by flow cytometry in B lineage cells
isolated from the spleens of ICR-WT, Em-TCL-1 Tg and PKCα-KR-HPC mice. Isotype control and ICR-T-cell-positive control are shown. (C) Protein
lysates were prepared from MIEV-FL or PKCa-KR-FL co-cultures at d10 and d16. Western blots were carried out, immunoblotting for phospho-
rylated and total ERK1/2, phosphorylated and total S6, and an additional loading control, GAPDH. (D) Proliferation was assessed by culturing
50,000 MIEV- or PKCa-KR cells from early (d6 – d10) and late (d15 – d20) stages of the cultures and incubating cells with BrdU for 2 h prior
to the end of the 24 h timepoint. Data are represented as mean (± SEM) of at least three biological replicates, each carried out in technical
triplicates. (E) Ki-67 expression levels (MFI) were analyzed in CD19-MACS-purified ICR-WT and PKCa-KR-HPC spleens. (F) RNA was isolated
from MIEV- or PKCa-KR-OP9 cells derived from early (d6 – d10) and late (d15 – d20) stages of the cultures and subjected to quantitative
reverse transcription-PCR to evaluate the levels of aicda expression. Results are expressed as 2(-DDCT) relative to the GAPDH reference gene.
Data are represented as mean (± SEM) of at least three biological replicates, each carried out in technical triplicates. A Student unpaired t-
test was performed; *P<0.05, ** P<0.005.  
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sion.21 Analysis of PKCa-KR-transduced cells revealed up-
regulation of both prkcb expression (Online Supplementary
Figure S5) and PKCbII protein expression in PKCa-KR-
transduced cells compared with the levels in MIEV control
cells, while PKCbI expression was unaltered (Figure 4C).
To determine the stage at which PKCbII is up-regulated
during the development of CLL-like cells on OP9 co-cul-
ture, MIEV- or PKCa-KR co-cultures were harvested as
indicated and PKCbII expression was determined. PKCbII
expression increased between d10 and d15 of co-culture in
PKCa-KR-transduced cells, while remaining unchanged in
MIEV control cells (Figure 4D). Up-regulation of PKCbII
and concomitant down-regulation of PKCa expression
has previously been shown in CLL patients’ samples,21,22 a
finding that was confirmed in our CLL cohort. Compared
to PKCa expression in peripheral blood B lymphocytes
obtained from healthy volunteers, PKCa was barely
detectable in the majority of CLL samples (12/16 samples),
while PKCbII expression was elevated in half of the sam-
ples assessed (Figure 4E). Analysis of this cohort did not
indicate an association of absent/low PKCa expression
with a specific prognostic subgroup of CLL patients
(Online Supplementary Table S1). PKCa expression was
down-regulated in B cells isolated from Em-TCL-1 spleens
compared with the expression in age-matched, wild-type
controls; the difference did not, however, reach statistical
significance (Figure 4F). Interestingly PKCa expression
was also down-regulated in PKCa-KR-expressing splenic
B cells. There was a trend towards up-regulation of
PKCbII expression in in vivo-generated PKCa-KR B cells
but not in purified Em-TCL-1 splenic B cells, which exhib-
ited similar PKCbII expression to that of age-matched,
control B cells (Figure 4F). Analysis of the ERK-MAPK-
mTor signaling pathway in vivo demonstrated a significant
activation of mTor kinase, as indicated by the elevation in
phosphorylated S6 both in PKCa-KR-expressing and Em-
TCL-1 splenic B cells (Figure 4G). However, pERK exhibit-
ed variability between mice and so there was not a clear
up-regulation of ERK-MAPK activity.
Our CLL-like cells exhibit a higher expression of mark-
ers associated with adverse outcome in CLL patients and
possess an enhanced proliferation capacity, likely due to
elevated mTor signaling upon PKCa subversion. This,
coupled with the finding that PKCa expression is reduced
in the majority of CLL patients’ samples assessed, indi-
cates that our CLL-like disease model is a translationally-
relevant model for the progressive human disease.
PKCb selective inhibitors inhibit chronic lymphocytic
leukemia-like cell proliferation in vitro and in vivo
To determine whether PKCb plays an important role in
driving proliferation and cell survival in our mouse CLL-
like disease model in vitro, CLL-like cells were treated with
the PKCb selective inhibitor, enzastaurin.  PKCb has pre-
viously been shown to phosphorylate and inhibit
GSK3b.23 Therefore, to test the selectivity of enzastaurin
for PKCb-mediated signals, we assessed the phosphoryla-
tion status of GSK3b. PKCa-KR-expressing cells from late
co-cultures exhibited increased phospho-GSK3bS9, an
effect that was abrogated by enzastaurin treatment (20
mM; Figure 5A). Enzastaurin treatment induced a selective
and significant elevation in apoptosis above background
both in PKCa-KR-expressing cells (left) and splenic Em-
TCL-1 cells (right) compared with control cells, as indicat-
ed by an elevation in the percentage of annexin V+DAPI-
cells among the leukemic cells (Figure 5B, Online
Supplementary Figure S6). 
Analysis of the effect of enzastaurin treatment on cellu-
lar proliferation revealed a G1 arrest in PKCa-KR-cultures
only (Figure 5C, left). This was accompanied by a signifi-
cant reduction in the proportion of cells undergoing mito-
sis in PKCa-KR-cultures (Figure 5C, right). Coupled with
R. Nakagawa et al.
504 haematologica | 2015; 100(4)
Table 1. Summary of IGVH rearrangements generated in mice transplanted with MIEV- or PKCa-KR-expressing cells. GFP+ leukemic B cells gen-
erated in vivo were isolated prior to cloning and sequencing of IGVH regions. Sequences were analyzed using IMGT (www.imgt.org). In-frame
sequences are shown.
Sample N. VH gene JH gene DH gene Similarity to germline (%) Mutational status CDR3 length
MIEV-1 IGHV1-9*01 IGHJ4*01 IGHD2-3*01 99.7 UM 14
MIEV-2 IGHV1S20*02 IGHJ2*01 IGFD1-1*01 98.6 UM 11
MIEV-3 IGHV1S132*01 IGFJ4*01 IGHD1-1*02 98.6 UM 13
MIEV-4 IGV5-4*02 IGHJ3*01 IGHD4-1*01 97.1 M 11
MIEV-5 IGHV1S15*01 IGHJ3*01 IGHD2-3*01 98.3 UM 9
MIEV-6 IGHV14-1*01 IGHJ3*01 IGHD2-12*01 97.1 M 13
MIEV-7 IGHV1-63*02 IGHJ1*01 IGHD2-1*01 97.1 M 11
MIEV-8 IGHV1-9*01 IGHJ4*01 IGHD2-3*01 97.6 M 14
PKCa-KR-1 IGHV1-39*01 IGHJ4*01 IGHD2-1*01 98.6 UM 12
PKCa-KR-2 IGV1S20*02 IGHJ2*01 IGHD1-1*01 93.3 M 14
PKCa-KR-3 IGHV1-63*02 IGHJ4*01 IGHD3-2*02 97.1 M 14
PKCa-KR-4 IGHV1-39*01 IGHJ4*01 IGHD2-1*01 100 UM 12
PKCa-KR-5 IGHV1-69*02 IGHJ1*03 IGHD1-1*01 98.9 UM 16
PKCa-KR-6 IGHV1-23*01 IGHJ1*01 IGHD1-1*01 99.3 UM 13
PKCa-KR-7 IGHV14-4*01 IGHJ3*01 IGHD1-1*01 99 UM 14
PKCa-KR-8 IGHV81*01 IGHJ2*01 IGHD2-1*01 99 UM 13
M: mutated; UM: unmutated.
these data, enzastaurin treatment significantly reduced the
BrdU incorporation of PKCa-KR cells at 24 and 48 h
(Figure 5D). In addition, and supporting the data presented
in Figure 3D, PKCa-KR-expressing cells exhibited a signif-
icantly higher proliferation rate than MIEV cells in untreat-
ed cultures, and treatment of these cells with enzastaurin
reduced their proliferation rate to that of MIEV cells
(Figure 5D). These results demonstrate that enzastaurin
selectively inhibited cell cycle progression and prolifera-
tion in CLL-like cells in vitro.
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Figure 4. CLL cells isolated from mouse models and CLL patients samples exhibit altered PKC isoform expression profiles. (A) Protein lysates
were prepared from MIEV- or PKCa-KR-HPC derived cells at the indicated times, separated by gel electrophoresis and immunoblotted for PKC
substrates using the anti-phospho-Ser PKC substrate antibody (pSer-PKC-substrate). GAPDH was included as a protein loading control. (B)
Protein kinase assay was carried out on cells prepared from d17 MIEV- or PKCa-KR-OP9 co-cultures. A Student unpaired t-test was performed;
*P<0.05. (C) Protein lysates were prepared from MIEV- or PKCa-KR-OP9 co-cultures and immunoblotted for PKCbI, PKCbII and GAPDH as a
protein loading control. (D) Protein lysates were prepared from earlier and later MIEV- or PKCa-KR-OP9 co-cultures as indicated and
immunoblotted for PKCbII and GAPDH as a protein loading control. (E) Protein lysates were prepared from B lineage cells of freshly isolated
peripheral blood samples derived from healthy donors or CLL patients. Membranes were immunoblotted for PKCa, PKCbII and GAPDH as a
protein loading control. (F) Protein lysates were prepared from MACS-isolated spleen B cells from age-matched C57BL/6 (n=5), Em-TCL-1 Tg
(n=5) and PKCa-KR-expressing (n=4) mice and immunoblotted for PKCα, PKCbII and GAPDH as a protein loading control. A representative
blot (left) and the mean expression (±SEM) of PKCa (left) and PKCbII (right) as a ratio of GAPDH are shown. (G) Protein lysates were prepared
from MACS-isolated spleen B cells of Em-TCL-1 Tg (n=5), PKCa-KR-expressing (n=4) and age-matched C57BL/6 (n=5) mice and immunoblot-
ted for pERK/ERK and pS6/S6. A representative blot (left) and the mean expression (±SEM) of pERK as a ratio of ERK (left) and pS6 as a
ratio of S6 (right) are shown.
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To test the efficacy of enzastaurin at inhibiting prolifer-
ation of CLL-like cells in vivo, mice were treated with
enzastaurin twice a day for up to 3 weeks, after confirma-
tion that the mice were leukemic (≥0.4% GFP+CD19+CD5+
cells in the blood). Enzastaurin-treated mice displayed a
decrease in the percentage and number of
GFP+CD19+CD5+ cells in the bone marrow, spleen, lymph
nodes and blood compared with vehicle-treated controls,
with the differences reaching significance in the bone mar-
row, spleen and blood (Figure 6A-C). Interestingly, a
decrease in CLL-like cells in the blood was observed dur-
ing treatment, although this did not reach statistical signif-
icance. In addition, there was a significant induction of
apoptosis in enzastaurin-treated CLL-like cells in both the
bone marrow and spleen, compared with the apoptosis of
vehicle-treated CLL cells (Figure 6D). Collectively, these
results indicate that targeted therapies towards PKCb-
mediated signaling pathways show promise as potential
therapies for progressive CLL, by impeding CLL cell pro-
liferation and inducing apoptosis.
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Figure 5. Enzastaurin induced
cell cycle arrest and apoptosis
in CLL-like cells. MIEV- or
PKCa-KR-HPC-derived cells
were cultured for 24 hr in the
presence of enzastaurin
(ENZA) as indicated. (A)
Protein lysates were prepared
from late co-cultures (post-
d15) of MIEV- or PKCa-KR-
expressing cells. Proteins sep-
arated by gel electrophoresis
and immunoblotted for phos-
pho-GSK3bS9, GSK3b and
tubulin as a protein loading
control. Densitometry was per-
formed on the blots, assess-
ing the phospho-GSK3bS9 sig-
nal compared with GSK3b sig-
nal strength. The mean per-
centage (± SEM) of phospho-
GSK3b signal reduction from
untreated cells in three inde-
pendent experiments is
shown. (B) Flow cytometry
was used to assess the level
of apoptosis induced by enza-
staurin treatment of MIEV- vs.
PKCa-KR cells and splenic B
lineage cells isolated from
age-matched C57BL/6 vs. Em-
TCL-1 transgenic mice.
Annexin V+DAPI- cells repre-
sent early apoptotic cells.
Data are represented as
mean (± SEM) of three biolog-
ical replicates. (C) PI analysis
was used to calculate the
phases of the cell cycle (G0/G1
and G2M shown).  Data shown
exclude the sub-G0 population.
Data are represented as
mean (± SEM) of at least three
biological replicates. Open cir-
cle ( ) PKCa-KR; filled circle (
) MIEV. (D) MIEV- or PKCa-KR-
expressing cells were cultured
for 24 or 48 h in the presence
of ENZA, as indicated. Cells
were incubated with BrdU for
2 h prior to the end of the
timepoint. Absorbance values
were read at 492 nm to 370
nm after addition of TMB sub-
strate. Data shown are the
mean (± SEM) of at least three
biological replicates, each car-
ried out in technical tripli-
cates. P values were generat-
ed using the Student unpaired
t-test *P<0.05, **P<0.005,
***P<0.001. 
D
B
C
A MIEV PKCa-KR
MIEV PKCa-KR
MIEV
a-KR
ns ns
C57BL/6
TCL-1
ENZA
pGSK3b
GSK3b
Tubulin
30
20
10
0
80
70
60
50
40
30
20
10
0
25
20
15
10
5
0
0 10 20 30 40 50
Enzastaurin (mM)
0 10 20 50 0 10 20 50
Enzastaurin (mM)
0 10 20 50 0 10 20 50
Enzastaurin (mM)
0 10 20 30 40 50
Enzastaurin (mM)
0 10 20 30 40 50
Enzastaurin (mM)
Pr
ol
ife
ra
tio
n 
(B
rd
U 
OD
)
%
 G
0/G
1
%
 A
nn
V+
DA
PI
-
%
 A
nn
V+
DA
PI
-
%
 G
2/M
0 10 20 30 40 50
Enzastaurin (mM)
24 h 48 h
%
 re
du
ct
io
n 
in
 p
GS
K3
b
w
ith
 E
NZ
A
90
80
70
60
50
1.3
1.2
1.1
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
30
20
10
0
0.75
0.50
0.25
0.00
Discussion
We previously established that subversion of PKCa con-
fers a CLL-like phenotype to B lineage cells both in vitro
and in vivo.9 We now demonstrate that PKCa-KR-express-
ing CLL-like cells display poor prognostic features of the
human disease both in vitro and in vivo, and aberrantly
expand in lymphoid organs of mice in vivo. These CLL-like
cells exhibit elevated proliferation, likely due to an activa-
tion of ERK-MAPK-mTor signaling, indicating that PKCa-
KR-expressing cells display properties of progressive dis-
ease. Importantly, we demonstrated that PKCa expression
was down-regulated in the majority of CLL cases
assessed, indicating that this model is translationally rele-
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Figure 6. Enzastaurin (ENZA) reduced leukemic burden and selectively induced apoptosis in CLL-like cells in vivo.  CLL-like diseased mice were
generated by adoptively transferring 4x105 PKCa-KR-FL cells into RAG-1-/- neonates.  Four to six weeks after injection, on confirmation of a
population of CLL-like cells in the blood (≥ 0.4%), mice were dosed with either ENZA or vehicle control 5% dextrose in water (D5W) for up to
21 days. Thereafter, blood, bone marrow (BM), spleen (SP) and lymph nodes (LN) were analyzed for leukemic burden and level of apoptosis
by flow cytometry as indicated. (A) Representative flow cytometric analysis of vehicle- or ENZA-treated mice. Data shown were analyzed for
CLL cell markers, CD19 and CD5 after live- and size- (FSC/SSC), GFP+ and CD45+ gating. The percentage of GFP+ CLL-like cells within the total
population is shown. (B) Percentages (left) and numbers (right) of the GFP+CD45+CD19+CD5+ population are shown in the ENZA- and D5W-
treated mice in the organs indicated. (C) Percentages of GFP+CD45+CD19+CD5+ cells in the blood before, during, and after ENZA-treatment
and vehicle administration. (D) Percentages of annexin V+7-AAD- apoptosing cells were calculated within the GFP+CD19+ population of ENZA-
and vehicle-treated mice. Data shown are the mean (± SEM) of six individual mice. P values were generated using the Student unpaired t-test
*P<0.05, **P<0.005.
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vant for the study of CLL. Subsequent to PKCa-KR
expression we identified an elevation in PKCbII expres-
sion, a PKC isoform that has been implicated in CLL
pathogenesis, which, when inhibited with enzastaurin,
reduced tumor load within the spleen, due to the induc-
tion of cell cycle arrest and apoptosis. 
Expression patterns of specific PKC isoforms are dysreg-
ulated in a number of cancers. PKCa is up-regulated in
breast, gastric, prostate and brain cancers, suggesting that
it contributes to tumorigenesis,24,25 and higher expression
levels have been linked with the aggressiveness and inva-
sive capacity of breast cancer cells.26,27 However, PKCa
expression is down-regulated in epidermal, pancreatic,
and colon cancers28-32 and CLL21 suggesting that PKCa can
also function as a tumor suppressor. This was demonstrat-
ed in mouse models for colon cancer, in which a reduction
in PKCa expression was observed in carcinogen-induced
colon cancer,32 and APCmin/+ mice.33 Indeed, crossing
APCmin/+ mice onto the PKCa-/- background led to an accel-
erated, more aggressive development of colon cancer.33,34
Interestingly, spontaneous development of cancerous
lesions in the intestinal tract occurred with higher frequen-
cy in aging PKCa-/- mice than in littermate controls.  The
malignant cells within the lesions derived from PKCa-/-
mice had a higher mitotic index than that of cells from lit-
termate controls. Taken together, these data strongly sug-
gest a role for PKCa in the regulation of cell division and
suppression of tumor formation in selected cancers.33 Of
note, PKCbII up-regulation has been intrinsically linked to
the development of colon cancer.32,35 Similarly, PKCb has
recently been shown to be essential for CLL development
in the TCL-1 Tg CLL mouse model, with deletion of PKCb
in a murine model of CLL leading to an increase in sur-
vival.36 Surprisingly, we found that PKCbII expression
remained unchanged in B lineage cells isolated from TCL-
1 Tg splenic cells; however, a reduction in PKCa expres-
sion was observed. Down-regulation of PKCa expres-
sion/function may contribute to the development/progres-
sion of CLL in both TCL-1 Tg mice and the PKCa-KR
mouse model, similar to the effect noted in colon cancer
models. Interestingly, PKCa expression was also reduced
in the PKCa-KR mouse model, whilst GFP expression was
maintained. This finding suggests that PKCa may be post-
translationally targeted for degradation in CLL cells, result-
ing in decreased expression.37 Results from the in vitro co-
cultures of our model indicate that up-regulated PKCbII is
not required for the initiation of CLL-like cells, as
GFP+CD19+CD5+ cells were present during the early stages
of the cultures, prior to PKCbII up-regulation. These
results suggest that loss of PKCa function may create per-
missive conditions for the generation of CLL, while
PKCbII activation/up-regulation enables disease progres-
sion. Indeed, the block in CLL development in the PKCb-
/--TCL-1 Tg model may reflect the absence of both PKCbI
and PKCbII in these mice.
Mouse models form an integral part of the pre-clinical
development of promising therapies.38 Due to the hetero-
geneity of CLL, it is important to generate models that
represent the complexity of the disease. For example tar-
geting a component of the 13q deletion incorporating the
DLEU gene product in mice, present in over 50% of
patients, resulted in the development of CLL.39 In addition,
the development of a CLL phenotype in Em-TCL-1 Tg
mice resulted in subsequent studies establishing that TCL-
1 is preferentially expressed in patients with a poor prog-
nosis.40,41 Here, we demonstrated that CLL cells express
lower levels of PKCa than their normal B-cell counterparts
suggesting that reduced expression levels of PKCa may
assist in generating permissive conditions for the develop-
ment of CLL. Like the TCL-1 Tg mouse, our model pre-
dominantly expresses unmutated IGVH genes that have
longer CDR3 regions, a characteristic of subsets of poor
prognostic CLL patients.42,43 In contrast, ZAP-70 is up-reg-
ulated in PKCa-KR-expressing CLL-like cells while, as
shown previously, it is absent in TCL-1 splenic B cells,44
which may reflect a difference in the cell of origin
between these two models. These findings suggest that
the two mouse models provide complementary disease
systems for studying the pathogenesis of poor prognostic
CLL. Notably, an advantage of the PKCa-KR model over
the TCL-1 Tg mouse is the former’s rapid and reliable dis-
ease onset, in a timeframe of weeks compared to months,
which is beneficial when performing in vivo drug testing. 
Although the molecular basis of CLL has not been fully
understood, PKC-mediated signals control CLL survival
and proliferation, and thus represent promising therapeu-
tic targets. Enzastaurin has previously been shown to
induce apoptosis in CLL cells independently of mutational
status in an in vitro culture system.36 Enzastaurin-mediated
apoptosis has been reported to be dependent on PP2A
activity.45 Interestingly, inhibition of PKC activity by treat-
ing cells with ruboxistaurin (targeting PKCb) or sotrastau-
rin (AEB071; a pan-PKC inhibitor) results in the down-reg-
ulation of the protein tyrosine kinase PTPN22, which
plays a protective role in BCR-mediated CLL survival,
leading to apoptosis in vitro.46 Our studies demonstrate a
selective induction of apoptosis in leukemic cells and a
reduction in cellular proliferation with enzastaurin in vitro
and in vivo. The enzastaurin-mediated reduction in prolif-
eration has previously been demonstrated in a number of
solid cancer models and myeloma cell lines.47 Proliferating
CLL cells are more prone to undergo clonal evolution,
which can result in the development of detrimental chro-
mosomal abnormalities including 17p deletions that target
p53, rendering the cells insensitive to first-line therapies
used for CLL.48 Indeed, up-regulation of activation-
induced deaminase has been associated with elevated
double-strand DNA breaks in CLL cells, promoting the
generation of genetic aberrations.20 Therapies that reduce
proliferation do, therefore, offer an important treatment
option for progressive CLL. Our findings support the
development of clinical studies with ruboxistaurin and
sotrastaurin in CLL, given the recent promising data
assessing the clinical efficacy of BCR-targeting inhibitors
such as the Btk inhibitor ibrutinib.49 In support of this,
AEB071 is currently being studied in a phase II clinical trial
in diffuse large B-cell lymphoma, and has recently been
demonstrated to have pre-clinical activity in CLL in vitro
and in vivo.50 Targeting PKC, and in particular PKCb, is
especially pertinent given the recent findings of Lutzny et
al., who demonstrated that PKCbII expression in bone
marrow stromal cells is essential for the survival and
development of CLL cells.51 Therefore, inhibition of PKCb
may modify the tumor microenvironment, which has
been established to play a critical role in supporting CLL
survival, proliferation and chemoresistance.52
Collectively, our results demonstrate the potential for
therapeutic agents targeting PI3K/PKCb−related signaling
pathways, and highlight the translational applicability of
the PKCa-KR mouse model as a pre-clinical model for the
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development of poor prognostic CLL. Moreover, our
mouse model provides a powerful tool for delineating the
molecular events that occur downstream of PKCa subver-
sion during the initiation of cellular transformation,
enabling the identification of potential novel therapeutic
targets for CLL. 
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